REG - Eco Animal Health Gp - Publication of Annual Report and Notice of AGM

ECO Animal HealthAnnouncement

02/09/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220902:nRSB9602Xa&default-theme=true

RNS Number : 9602X  Eco Animal Health Group PLC  02 September 2022

2 September 2022

ECO Animal Health Group plc (the "Company")

(AIM: EAH)

Annual Report and Accounts & Annual General Meeting

 

ECO Animal Health Group plc announces the publication of the following
documents ("the Documents") on the Company's website:
www.ecoanimalhealthgroupplc.com/investor-relations.aspx.

 

·     Annual Report and Accounts for the year ended 31 March 2022

·    Notice of Annual General Meeting to be held at The Grange, 100 High
Street, London, N14 6BN on 26 September 2022 at 11.30am ("AGM") and Form of
Proxy

 

The Documents will be posted today to those shareholders that have elected to
receive them by post.

 

For further information please contact:

                                                                 020 8447 8899

 ECO Animal Health Group plc

 David Hallas (CEO)

 Christopher Wilks (CFO)

 IFC Advisory                                                    020 3934 6630

 Graham Herring

 Zach Cohen

 Singer Capital Markets (Nominated Adviser & Joint Broker)       020 7496 3000

 Mark Taylor

 George Tzimas

 Investec (Joint Broker)                                         020 7597 5970

 Gary Clarence

 Brough Ransom

 Carlo Spingardi

 Peel Hunt LLP (Joint Broker)                                    020 7418 8900

 Dr Christopher Golden

 James Steel

 

 Equity Development  020 7065 2692

 Hannah Crowe

 Matt Evans

 

 About ECO Animal Health

ECO Animal Health Group plc researches, develops and commercialises products
for livestock. Our business strategy is to generate shareholder value by
achieving the maximum sales potential from the existing product portfolio
whilst investing in Research and Development ("R&D") for new products,
particularly vaccines, and seeking to in-license new products.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSZZGGLGMNGZZM